/PRNewswire/ Pathios Therapeutics Limited ("Pathios"), a biotech company focused on developing first-in-class therapies for cancer, today announced that.
Amphivena Therapeutics Announces First Patient Dosed in the Phase 1 Dose Expansion of AMV564
News provided by
Share this article
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2020 /PRNewswire/
Amphivena Therapeutics, a clinical-stage oncology company focused on developing a platform of bivalent T-cell engagers that restore anti-cancer immunity in patients, today announced the first patient has been dosed in the Phase 1 dose expansion study evaluating AMV564, an investigational, first-in-class agent that
depletes myeloid derived suppressor cells (MDSC) and activates T cells, in adult patients with selected solid tumor indications.
The dose escalation phase of the first-in-human, multicenter, open-label study of AMV564 in solid tumors was initiated in October 2019 and established the safety, PK profile and clinical activity of AMV564 including a confirmed RECIST complete response